Daksh Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.82 M
as on 24-10-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.81 Cr
as on 24-10-2024
- Satisfied Charges ₹ 3.00 M
as on 24-10-2024
- Revenue -4.23%
(FY 2023)
- Profit 10.65%
(FY 2023)
- Ebitda 6.09%
(FY 2023)
- Net Worth 11.24%
(FY 2023)
- Total Assets 13.93%
(FY 2023)
About Daksh Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.82 M.
The company currently has active open charges totaling ₹15.81 Cr. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Agarwal and Madhubala Agarwal serve as directors at the Company.
- CIN/LLPIN
U24232RJ2006PTC023241
- Company No.
023241
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2006
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jodhpur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Daksh Pharmaceuticals Private Limited offer?
Daksh Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Franchise, Allopathic PCD Pharma Franchise, Pharma & Bioanalytical Services, PCD Pharma Franchise.
Who are the key members and board of directors at Daksh Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Agarwal  | Director | 17-Oct-2006 | Current |
| Madhubala Agarwal | Director | 17-Oct-2006 | Current |
Financial Performance of Daksh Pharmaceuticals.
Daksh Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.23% decrease. The company also saw a substantial improvement in profitability, with a 10.65% increase in profit. The company's net worth Soared by an impressive increase of 11.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daksh Pharmaceuticals?
In 2023, Daksh Pharmaceuticals had a promoter holding of 33.87% and a public holding of 66.13%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹158.10 M
₹3.00 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 14.90 Cr
- Others : 0.91 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 May 2021 | Hdfc Bank Limited | ₹7.82 Cr | Open |
| 26 Apr 2018 | Others | ₹9.10 M | Open |
| 24 Apr 2015 | Hdfc Bank Limited | ₹7.09 Cr | Open |
| 30 Sep 2010 | Yes Bank Limited | ₹3.00 M | Satisfied |
How Many Employees Work at Daksh Pharmaceuticals?
Unlock and access historical data on people associated with Daksh Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daksh Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daksh Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.